A Trial of INO-1001 in Patients Undergoing Heart Surgery That Involves Heart-lung Bypass
Status:
Terminated
Trial end date:
2006-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the safety of INO-1001, an intravenous PARP (poly-[ADP
ribose] polymerase) inhibitor, in patients undergoing heart surgery. The study also measures
whether INO-1001 reduces the side effects caused by heart-lung bypass machines.